据路透社预测,Prolia在2024年的全球销售额将达到33亿美元。安进全球开发高级副总裁Elliott Levy表示,“Evenity定位为快速增加骨折风险患者的骨密度和降低骨折风险;在完成疗程治疗后,患者可继续使用抗吸收剂治疗,如Prolia。”
与阿仑膦酸组对照,Evenity组的心血管风险增加了30%——比较心血管复合终点事件(MACE)发生率,Evenity组 2.5%vs 阿仑膦酸1.9%。Evenity曾被视为安进骨松领域的重磅炸弹药物Prolia(denosumab)专利到期后的接班人。ARCH结果公布后,Jefferies 的分析师Michael Yee给出了5亿美金的峰值年销售额预估,综合该药的心血管风险和...
Evenity vs Prolia: Which is right for you? Evenity (romosozumab-aqqg) and Prolia (denosumab) are two injectable medications that help lower the risk of bone fracture. When deciding which treatment option is best for you, it is important to consider factors such as who these medications are...